Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Valsartan | hsa00030 | Pentose phosphate pathway | 1.69E-02 | 2 | P60891, P37837 | PRPS1, TALDO1 | More | | Valsartan | hsa00052 | Galactose metabolism | 1.03E-02 | 2 | P06280, O43451 | GLA, MGAM | More | | Valsartan | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | | Valsartan | hsa00071 | Fatty acid degradation | 3.65E-03 | 4 | O75521, P00325, P11766, P33121 | ECI2, ADH1B, ADH5, ACSL1 | More | | Valsartan | hsa00220 | Arginine biosynthesis | 2.86E-02 | 2 | P15104, P05089 | GLUL, ARG1 | More | | Valsartan | hsa00500 | Starch and sucrose metabolism | 9.97E-08 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Valsartan | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Valsartan | hsa00520 | Amino sugar and nucleotide sugar metabolism | 2.24E-02 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Valsartan | hsa00524 | Neomycin, kanamycin and gentamicin biosynthesis | 2.03E-02 | 1 | P35557 | GCK | More | | Valsartan | hsa00533 | Glycosaminoglycan biosynthesis - keratan sulfate | 1.91E-02 | 1 | Q9NY97 | B3GNT2 | More | | Valsartan | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | | Valsartan | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | | Valsartan | hsa00591 | Linoleic acid metabolism | 1.29E-03 | 1 | P11712 | CYP2C9 | More | | Valsartan | hsa00601 | Glycosphingolipid biosynthesis - lacto and neolacto series | 3.78E-02 | 1 | Q9NY97 | B3GNT2 | More | | Valsartan | hsa00730 | Thiamine metabolism | 5.15E-07 | 3 | Q9Y6K8, P05186, P24666 | AK5, ALPL, ACP1 | More | | Valsartan | hsa00740 | Riboflavin metabolism | 4.03E-02 | 1 | P24666 | ACP1 | More | | Valsartan | hsa00770 | Pantothenate and CoA biosynthesis | 7.90E-03 | 3 | O95498, O95497, Q9NRN7 | VNN2, VNN1, AASDHPPT | More | | Valsartan | hsa00830 | Retinol metabolism | 2.20E-02 | 4 | P00325, P11766, Q9BPW9, O75911 | ADH1B, ADH5, DHRS9, DHRS3 | More | | Valsartan | hsa00860 | Porphyrin and chlorophyll metabolism | 1.69E-02 | 2 | P36551, P30043 | CPOX, BLVRB | More | | Valsartan | hsa00920 | Sulfur metabolism | 1.78E-02 | 1 | Q16762 | TST | More | | Valsartan | hsa00970 | Aminoacyl-tRNA biosynthesis | 6.08E-09 | 4 | O95363, P54136, P14868, Q15046 | FARS2, RARS1, DARS, KARS | More | | Valsartan | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Valsartan | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | | Valsartan | hsa00983 | Drug metabolism - other enzymes | 2.44E-02 | 2 | P32320, P05164 | CDA, MPO | More | | Valsartan | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Valsartan | hsa01210 | 2-Oxocarboxylic acid metabolism | 1.91E-02 | 1 | P50213 | IDH3A | More | | Valsartan | hsa01230 | Biosynthesis of amino acids | 3.59E-02 | 3 | P60891, Q99707, P37837 | PRPS1, MTR, TALDO1 | More | | Valsartan | hsa01523 | Antifolate resistance | 1.68E-02 | 2 | Q92820, P04818 | GGH, TYMS | More | | Valsartan | hsa01524 | Platinum drug resistance | 1.02E-03 | 7 | P10415, Q13489, O15392, P78417, P23025, P11388, P43246 | BCL2, BIRC3, BIRC5, GSTO1, XPA, TOP2A, MSH2 | More | | Valsartan | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | | Valsartan | hsa03008 | Ribosome biogenesis in eukaryotes | 1.31E-04 | 7 | Q9NYH9, O14980, O60832, P78345, Q9BVP2, O15381, Q9GZY0 | UTP6, XPO1, DKC1, RPP38, GNL3, NVL, NXF2; NXF2B | More | | Valsartan | hsa03013 | RNA transport | 2.97E-10 | 20 | O14980, P52298, Q09161, O14893, P61326, Q15287, Q9UBU9, Q7Z3B4, P35658, P63279, Q14152, P55884, O15371, O75822, P78345, P20042, Q14240, P23588, Q9Y6A5, P51114 | XPO1, NCBP2, NCBP1, GEMIN2, MAGOH, RNPS1, NXF1, NUP54, NUP214, UBE2I, EIF3A, EIF3B, EIF3D, EIF3J, RPP38, EIF2S2, EIF4A2, EIF4B, TACC3, FXR1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q92769 | HDAC2 | Histone deacetylase 2 | O14980 | XPO1 | Exportin-1 | 0.75 | P21462 | FPR1 | fMet-Leu-Phe receptor | O14980 | XPO1 | Exportin-1 | -0.742 | Q92769 | HDAC2 | Histone deacetylase 2 | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | 0.766 | P08246 | ELA2 | Neutrophil elastase | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | -0.852 | P21462 | FPR1 | fMet-Leu-Phe receptor | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | -0.874 | P51684 | CCR6 | C-C chemokine receptor type 6 | P52298 | NCBP2 | Nuclear cap-binding protein subunit 2 | 0.924 | P08246 | ELA2 | Neutrophil elastase | Q09161 | NCBP1 | Nuclear cap-binding protein subunit 1 | -0.732 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q09161 | NCBP1 | Nuclear cap-binding protein subunit 1 | -0.78 | Q92769 | HDAC2 | Histone deacetylase 2 | O14893 | GEMIN2 | Gem-associated protein 2 | 0.734 | P08246 | ELA2 | Neutrophil elastase | O14893 | GEMIN2 | Gem-associated protein 2 | -0.785 | P21462 | FPR1 | fMet-Leu-Phe receptor | O14893 | GEMIN2 | Gem-associated protein 2 | -0.87 | P51684 | CCR6 | C-C chemokine receptor type 6 | O14893 | GEMIN2 | Gem-associated protein 2 | 0.771 | Q92769 | HDAC2 | Histone deacetylase 2 | P61326 | MAGOH | Protein mago nashi homolog | 0.812 | P21462 | FPR1 | fMet-Leu-Phe receptor | P61326 | MAGOH | Protein mago nashi homolog | -0.835 | P51684 | CCR6 | C-C chemokine receptor type 6 | P61326 | MAGOH | Protein mago nashi homolog | 0.704 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Q15287 | RNPS1 | RNA-binding protein with serine-rich domain 1 | 0.756 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | Q9UBU9 | NXF1 | Nuclear RNA export factor 1 | 0.723 | Q92769 | HDAC2 | Histone deacetylase 2 | Q7Z3B4 | NUP54 | Nucleoporin p54 | 0.775 | P08246 | ELA2 | Neutrophil elastase | Q7Z3B4 | NUP54 | Nucleoporin p54 | -0.723 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q7Z3B4 | NUP54 | Nucleoporin p54 | -0.903 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q7Z3B4 | NUP54 | Nucleoporin p54 | 0.811 | Q92769 | HDAC2 | Histone deacetylase 2 | P35658 | NUP214 | Nuclear pore complex protein Nup214 | -0.729 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P35658 | NUP214 | Nuclear pore complex protein Nup214 | -0.725 | P08246 | ELA2 | Neutrophil elastase | P35658 | NUP214 | Nuclear pore complex protein Nup214 | 0.765 | P21462 | FPR1 | fMet-Leu-Phe receptor | P35658 | NUP214 | Nuclear pore complex protein Nup214 | 0.971 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P63279 | UBE2I | SUMO-conjugating enzyme UBC9 | 0.736 | Q92769 | HDAC2 | Histone deacetylase 2 | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | 0.719 | P08246 | ELA2 | Neutrophil elastase | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | -0.722 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | -0.89 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q14152 | EIF3A | Eukaryotic translation initiation factor 3 subunit A | 0.701 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P55884 | EIF3B | Eukaryotic translation initiation factor 3 subunit B | -0.731 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | O15371 | EIF3D | Eukaryotic translation initiation factor 3 subunit D | 0.77 | P08246 | ELA2 | Neutrophil elastase | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | -0.825 | P21462 | FPR1 | fMet-Leu-Phe receptor | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | -0.953 | P51684 | CCR6 | C-C chemokine receptor type 6 | O75822 | EIF3J | Eukaryotic translation initiation factor 3 subunit J | 0.711 | P08246 | ELA2 | Neutrophil elastase | P78345 | RPP38 | Ribonuclease P protein subunit p38 | -0.795 | P51684 | CCR6 | C-C chemokine receptor type 6 | P78345 | RPP38 | Ribonuclease P protein subunit p38 | 0.861 | P49354 | FNTA | Protein farnesyltransferase/geranylgeranyltransferase type-1 subunit alpha | P20042 | EIF2S2 | Eukaryotic translation initiation factor 2 subunit 2 | 0.733 | Q92769 | HDAC2 | Histone deacetylase 2 | Q14240 | EIF4A2 | Eukaryotic initiation factor 4A-II | 0.79 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q14240 | EIF4A2 | Eukaryotic initiation factor 4A-II | -0.721 | Q92769 | HDAC2 | Histone deacetylase 2 | P23588 | EIF4B | Eukaryotic translation initiation factor 4B | 0.767 | Q92769 | HDAC2 | Histone deacetylase 2 | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | -0.758 | P08246 | ELA2 | Neutrophil elastase | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | 0.849 | P21462 | FPR1 | fMet-Leu-Phe receptor | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | 0.904 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9Y6A5 | TACC3 | Transforming acidic coiled-coil-containing protein 3 | -0.732 | P21462 | FPR1 | fMet-Leu-Phe receptor | P51114 | FXR1 | Fragile X mental retardation syndrome-related protein 1 | -0.713 |
| Valsartan | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Valsartan | hsa03020 | RNA polymerase | 4.40E-02 | 2 | P24928, P62487 | POLR2A, POLR2G | More | | Valsartan | hsa03040 | Spliceosome | 4.09E-08 | 19 | Q14562, O43143, O60508, Q99633, P08579, Q15427, P26368, P38159, P61978, Q13595, Q07955, Q01130, P84103, Q13243, Q9UMS4, P11142, Q9Y2W2, O43447, O75643 | DHX8, DHX15, CDC40, PRPF18, SNRPB2, SF3B4, U2AF2, RBMX, HNRPK, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, PRPF19, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Valsartan | hsa03060 | Protein export | 1.43E-02 | 2 | P37108, Q15005 | SRP14, SPCS2 | More | | Valsartan | hsa03450 | Non-homologous end-joining | 4.21E-02 | 1 | P13010 | XRCC5 | More | | Valsartan | hsa04012 | ErbB signaling pathway | 3.74E-02 | 3 | P21860, Q13557, O14944 | ERBB3, CAMK2D, EREG | More | | Valsartan | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Valsartan | hsa04015 | Rap1 signaling pathway | 9.35E-04 | 12 | P20827, P49767, P63261, Q96FS4, P11215, P25116, Q13009, Q7LDG7, P42338, P0DP23, P17252, P19174 | EFNA1, VEGFC, ACTG1, SIPA1, ITGAM, F2R, TIAM1, RASGRP2, PIK3CB, CALM1, PRKCA, PLCG1 | More | | Valsartan | hsa04020 | Calcium signaling pathway | 2.59E-06 | 12 | Q96DU7, P45880, Q16566, Q13557, P17252, P21860, O15399, P25116, P0DP23, P51828, P23634, P49767 | ITPKC, VDAC2, CAMK4, CAMK2D, PRKCA, ERBB3, GRIN2D, F2R, CALM1, ADCY7, ATP2B4, VEGFC | More | | Valsartan | hsa04022 | cGMP-PKG signaling pathway | 3.25E-03 | 8 | Q99941, P18848, P23634, Q8WYR1, P51828, P05141, P45880, P0DP24 | CREBL1, ATF4, ATP2B4, PIK3R5, ADCY7, SLC25A5, VDAC2, CALM2 | More | | Valsartan | hsa04024 | cAMP signaling pathway | 2.84E-02 | 5 | P0DP23, P23634, Q16566, O15399, P25116 | CALM1, ATP2B4, CAMK4, GRIN2D, F2R | More | | Valsartan | hsa04060 | Cytokine-cytokine receptor interaction | 9.80E-04 | 16 | P27930, P14778, P26842, Q9UHF4, Q13651, P16871, P25024, Q9UBD3, P47992, P02775, P09341, P32248, P51684, P18510, P09603, P01730 | IL1R2, IL1R1, CD27, IL20RA, IL10RA, IL7R, CXCR1, XCL2, XCL1, PPBP, CXCL1, CCR7, CCR6, IL1RN, CSF1, CD4 | More | | Valsartan | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 2.44E-05 | 12 | P51684, P32248, P09341, P19875, P25024, P02775, P25025, P47992, Q9UBD3, P14784, Q9UHF4, P01375 | CCR6, CCR7, CXCL1, CXCL2, CXCR1, PPBP, CXCR2, XCL1, XCL2, IL2RB, IL20RA, TNF | More | | Valsartan | hsa04062 | Chemokine signaling pathway | 9.51E-06 | 19 | P25024, P25025, P09341, P19875, P47992, Q9UBD3, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q08881, Q7LDG7, Q13009, P49841, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, XCL1, XCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, ITK, RASGRP2, TIAM1, GSK3B, PIK3R5 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | -0.803 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | 1 | Q13547 | HDAC1 | Histone deacetylase 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | 0.929 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P47992 | XCL1 | Lymphotactin | -0.706 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q9UBD3 | XCL2 | Cytokine SCM-1 beta | -0.706 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P09769 | FGR | Tyrosine-protein kinase Fgr | 0.796 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.971 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P07948 | LYN | Tyrosine-protein kinase Lyn | 0.707 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | Q13547 | HDAC1 | Histone deacetylase 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | -0.864 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.727 | Q13547 | HDAC1 | Histone deacetylase 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | -0.716 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.743 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43250 | GRK6 | G protein-coupled receptor kinase 6 | 0.818 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49407 | ARRB1 | Beta-arrestin-1 | -0.721 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13009 | TIAM1 | Rho guanine nucleotide exchange factor TIAM1 | 0.706 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q8WYR1 | PIK3R5 | Phosphoinositide 3-kinase regulatory subunit 5 | 0.752 |
| Valsartan | hsa04064 | NF-kappa B signaling pathway | 2.28E-08 | 22 | P10415, Q13489, P25963, P51617, O00463, Q13546, P14778, P01584, P01375, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, Q13315, P24522, P09341, P19875, Q06643, Q9NQC7 | BCL2, BIRC3, NFKBIA, IRAK1, TRAF5, RIPK1, IL1R1, IL1B, TNF, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, ATM, GADD45A, CXCL1, CXCL2, LTB, CYLD | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08246 | ELA2 | Neutrophil elastase | P10415 | BCL2 | Apoptosis regulator Bcl-2 | -0.942 | P51684 | CCR6 | C-C chemokine receptor type 6 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.84 | P08246 | ELA2 | Neutrophil elastase | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | -0.716 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P08246 | ELA2 | Neutrophil elastase | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | -0.734 | P51684 | CCR6 | C-C chemokine receptor type 6 | P51617 | IRAK1 | Interleukin-1 receptor-associated kinase 1 | 0.722 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.932 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.837 | P08246 | ELA2 | Neutrophil elastase | O00463 | TRAF5 | TNF receptor-associated factor 5 | -0.814 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q13546 | RIPK1 | Receptor-interacting serine/threonine-protein kinase 1 | -0.868 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | 0.869 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.796 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.73 | P08246 | ELA2 | Neutrophil elastase | Q13077 | TRAF1 | TNF receptor-associated factor 1 | -0.725 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.768 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.958 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.875 | P08246 | ELA2 | Neutrophil elastase | Q16548 | BCL2A1 | Bcl-2-related protein A1 | 0.766 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q8WV28 | BLNK | B-cell linker protein | -0.704 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | Q8WV28 | BLNK | B-cell linker protein | -0.816 | P08246 | ELA2 | Neutrophil elastase | Q13315 | ATM | Serine-protein kinase ATM | -0.742 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.819 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.796 | P08246 | ELA2 | Neutrophil elastase | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | 0.7 | P51684 | CCR6 | C-C chemokine receptor type 6 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.712 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | Q13547 | HDAC1 | Histone deacetylase 1 | Q06643 | LTB | Lymphotoxin-beta | 0.74 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9NQC7 | CYLD | Ubiquitin carboxyl-terminal hydrolase CYLD | 0.799 |
| Valsartan | hsa04066 | HIF-1 signaling pathway | 3.40E-02 | 3 | Q09472, P07195, P10415 | EP300, LDHB, BCL2 | More | | Valsartan | hsa04068 | FoxO signaling pathway | 3.52E-02 | 1 | Q96BR1 | SGK3 | More | | Valsartan | hsa04070 | Phosphatidylinositol signaling system | 4.07E-02 | 4 | P0DP23, Q14643, O14732, P17252 | CALM1, ITPR1, IMPA2, PRKCA | More | | Valsartan | hsa04071 | Sphingolipid signaling pathway | 6.39E-06 | 10 | P17252, P21453, Q9H228, P01375, Q13362, Q16537, Q9BX95, P04637, P10415, Q9UQC2 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, PPP2R5E, SGPP1, TP53, BCL2, GAB2 | More | | Valsartan | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Valsartan | hsa04080 | Neuroactive ligand-receptor interaction | 3.11E-04 | 10 | P08311, Q15722, P21453, Q9H228, P43657, O00398, P21462, P21730, P14416, P35318 | CTSG, LTB4R, S1PR1, EDG8, P2RY5, P2RY10, FPR1, C5AR1, DRD2, ADM | More | | Valsartan | hsa04110 | Cell cycle | 8.83E-05 | 11 | Q9UJX4, P06493, O60566, Q09472, P24522, P04637, P49918, P30304, P33981, P42773, P01106 | ANAPC5, CDK1, BUB1B, EP300, GADD45A, TP53, CDKN1C, CDC25A, TTK, CDKN2C, MYC | More | | Valsartan | hsa04115 | p53 signaling pathway | 3.57E-02 | 5 | P24522, Q13315, Q53FA7, O95067, P10415 | GADD45A, ATM, TP53I3, CCNB2, BCL2 | More | | Valsartan | hsa04120 | Ubiquitin mediated proteolysis | 4.82E-03 | 2 | Q9UBT2, Q14669 | SAE2, TRIP12 | More | | Valsartan | hsa04122 | Sulfur relay system | 1.78E-02 | 1 | Q16762 | TST | More | | Valsartan | hsa04136 | Autophagy - other | 4.02E-04 | 2 | O94817, Q9H1Y0 | ATG12, ATG5 | More | | Valsartan | hsa04141 | Protein processing in endoplasmic reticulum | 3.64E-02 | 5 | Q99941, O75460, P11142, Q9H3Z4, P07900 | CREBL1, ERN1, HSPA8, DNAJC5, HSP90AA1 | More | | Valsartan | hsa04144 | Endocytosis | 4.10E-02 | 3 | O75351, P62491, Q14161 | VPS4B, RAB11A, GIT2 | More | | Valsartan | hsa04145 | Phagosome | 1.22E-03 | 11 | P63261, Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P27824, P13765 | ACTG1, NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, CANX, HLA-DOB | More | | Valsartan | hsa04151 | PI3K-Akt signaling pathway | 1.67E-03 | 18 | P62753, P42338, P43657, O43521, P27348, P20827, P49767, P08238, Q8WYR1, P63218, P50151, O15335, Q13751, P14784, P18848, O00141, Q6ZUJ8, P30281 | RPS6, PIK3CB, P2RY5, BCL2L11, YWHAQ, EFNA1, VEGFC, HSP90AB1, PIK3R5, GNG5, GNG10, CHAD, LAMB3, IL2RB, ATF4, SGK, PIK3AP1, CCND3 | More | | Valsartan | hsa04210 | Apoptosis | 4.26E-06 | 17 | Q13315, P04637, P10415, Q13489, O76075, P25963, P01375, Q9NR28, O75460, P24522, Q16548, Q13077, O43521, P43234, Q9UBR2, P18848, Q14643 | ATM, TP53, BCL2, BIRC3, DFFB, NFKBIA, TNF, DIABLO, ERN1, GADD45A, BCL2A1, TRAF1, BCL2L11, CTSO, CTSZ, ATF4, ITPR1 | More | | Valsartan | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Valsartan | hsa04217 | Necroptosis | 5.66E-03 | 5 | P15104, P05141, P01584, P0C0S5, Q9H444 | GLUL, SLC25A5, IL1B, H2AFZ, CHMP4B | More | | Valsartan | hsa04261 | Adrenergic signaling in cardiomyocytes | 4.32E-03 | 9 | P51828, Q99941, Q16537, P0DP23, Q13557, P17252, P10415, P20020, P23634 | ADCY7, CREBL1, PPP2R5E, CALM1, CAMK2D, PRKCA, BCL2, ATP2B1, ATP2B4 | More | | Valsartan | hsa04330 | Notch signaling pathway | 4.34E-02 | 2 | Q92542, P46531 | NCSTN, NOTCH1 | More | | Valsartan | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | | Valsartan | hsa04350 | TGF-beta signaling pathway | 4.88E-02 | 1 | P37173 | TGFBR2 | More | | Valsartan | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Valsartan | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Valsartan | hsa04380 | Osteoclast differentiation | 2.05E-03 | 12 | Q9NQC7, Q9UQC2, Q16539, P23458, P06239, P01584, P14778, O75015, Q8WV28, P01375, Q15080, P78324 | CYLD, GAB2, MAPK14, JAK1, LCK, IL1B, IL1R1, FCGR3B, BLNK, TNF, NCF4, SIRPA | More | | Valsartan | hsa04390 | Hippo signaling pathway | 2.11E-03 | 6 | P63261, Q13485, O15105, Q9UJU2, O43623, Q13489 | ACTG1, SMAD4, SMAD7, LEF1, SNAI2, BIRC3 | More | | Valsartan | hsa04510 | Focal adhesion | 3.21E-02 | 6 | Q15942, P17252, Q13489, P10415, P49767, P63261 | ZYX, PRKCA, BIRC3, BCL2, VEGFC, ACTG1 | More | | Valsartan | hsa04514 | Cell adhesion molecules | 2.37E-02 | 2 | P16109, O00501 | SELP, CLDN5 | More | | Valsartan | hsa04520 | Adherens junction | 3.36E-02 | 4 | Q13485, Q9UJU2, O43623, P63261 | SMAD4, LEF1, SNAI2, ACTG1 | More | | Valsartan | hsa04530 | Tight junction | 3.70E-04 | 7 | P63261, P16989, P56750, O00501, Q92974, Q14247, P24844 | ACTG1, CSDA, CLDN17, CLDN5, ARHGEF2, CTTN, MYL9 | More | | Valsartan | hsa04540 | Gap junction | 4.76E-02 | 3 | P17252, Q13509, P68371 | PRKCA, TUBB3, TUBB2C | More | | Valsartan | hsa04610 | Complement and coagulation cascades | 1.29E-05 | 2 | P00734, P0C0L4 | F2, C4A | More | | Valsartan | hsa04612 | Antigen processing and presentation | 4.59E-04 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Valsartan | hsa04613 | Neutrophil extracellular trap formation | 2.09E-08 | 25 | P17252, P11215, O60603, P05164, P08246, Q9UM07, Q13547, Q92769, P0C0S5, Q6FI13, Q93077, P62807, P33778, O60814, P68431, P14598, Q15080, P20160, P08311, P49913, O75015, P21730, P21462, O43315, Q16539 | PRKCA, ITGAM, TLR2, MPO, ELA2, PADI4, HDAC1, HDAC2, H2AFZ, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC3, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, CAMP, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P08246 | ELA2 | Neutrophil elastase | P17252 | PRKCA | Protein kinase C alpha type | -0.735 | P51684 | CCR6 | C-C chemokine receptor type 6 | P17252 | PRKCA | Protein kinase C alpha type | 0.738 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P11215 | ITGAM | Integrin alpha-M | 0.734 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.762 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.842 | P08246 | ELA2 | Neutrophil elastase | O60603 | TLR2 | Toll-like receptor 2 | 0.853 | P51684 | CCR6 | C-C chemokine receptor type 6 | O60603 | TLR2 | Toll-like receptor 2 | -0.767 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P05164 | MPO | Myeloperoxidase | 0.717 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P05164 | MPO | Myeloperoxidase | 0.719 | P08246 | ELA2 | Neutrophil elastase | P05164 | MPO | Myeloperoxidase | 0.903 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08246 | ELA2 | Neutrophil elastase | 0.702 | P08246 | ELA2 | Neutrophil elastase | P08246 | ELA2 | Neutrophil elastase | 1 | P51684 | CCR6 | C-C chemokine receptor type 6 | P08246 | ELA2 | Neutrophil elastase | -0.706 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.736 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.813 | P08246 | ELA2 | Neutrophil elastase | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.889 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.759 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.7 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q92769 | HDAC2 | Histone deacetylase 2 | -0.7 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q92769 | HDAC2 | Histone deacetylase 2 | 0.702 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P0C0S5 | H2AFZ | Histone H2A.Z | 0.785 | P08246 | ELA2 | Neutrophil elastase | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.907 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | -0.86 | P11712 | CYP2C9 | Cytochrome P450 2C9 | Q93077 | HIST1H2AC | Histone H2A type 1-C | 0.754 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.753 | P51684 | CCR6 | C-C chemokine receptor type 6 | P33778 | H2BC3 | Histone H2B type 1-B | 0.704 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.717 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | P62807 | HIST1H2BC | Histone H2B type 1-C/E/F/G/I | 0.753 | P11712 | CYP2C9 | Cytochrome P450 2C9 | O60814 | H2BC12 | Histone H2B type 1-K | 0.728 | Q99527 | GPER1 | G-protein coupled estrogen receptor 1 | O60814 | H2BC12 | Histone H2B type 1-K | 0.793 | P11712 | CYP2C9 | Cytochrome P450 2C9 | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.845 | P08246 | ELA2 | Neutrophil elastase | P14598 | NCF1 | Neutrophil cytosol factor 1 | 0.762 | P51684 | CCR6 | C-C chemokine receptor type 6 | P14598 | NCF1 | Neutrophil cytosol factor 1 | -0.713 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.706 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.762 | P08246 | ELA2 | Neutrophil elastase | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.945 | P51684 | CCR6 | C-C chemokine receptor type 6 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | -0.803 | P08246 | ELA2 | Neutrophil elastase | P20160 | AZU1 | Azurocidin | 0.842 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P08311 | CTSG | Cathepsin G | 0.715 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08311 | CTSG | Cathepsin G | 0.744 | P08246 | ELA2 | Neutrophil elastase | P08311 | CTSG | Cathepsin G | 0.792 | P08246 | ELA2 | Neutrophil elastase | P49913 | CAMP | Cathelicidin antimicrobial peptide | 0.807 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.892 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.923 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.983 | P08246 | ELA2 | Neutrophil elastase | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.703 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.839 | P08246 | ELA2 | Neutrophil elastase | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.85 | P51684 | CCR6 | C-C chemokine receptor type 6 | P21462 | FPR1 | fMet-Leu-Phe receptor | -0.7 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O43315 | AQP9 | Aquaporin-9 | 0.918 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O43315 | AQP9 | Aquaporin-9 | 0.934 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.839 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 |
| Valsartan | hsa04614 | Renin-angiotensin system | 7.48E-03 | 4 | P50052, P15144, P08311, O75787 | AGTR2, ANPEP, CTSG, ATP6AP2 | More | | Valsartan | hsa04621 | NOD-like receptor signaling pathway | 3.10E-03 | 11 | Q14643, P25963, Q13489, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P49913, P12838 | ITPR1, NFKBIA, BIRC3, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CAMP, DEFA4 | More | | Valsartan | hsa04625 | C-type lectin receptor signaling pathway | 8.11E-03 | 9 | Q9ULY5, P01584, Q9NQC7, P20749, Q14643, P01375, Q13191, P0DP24, Q16539 | CLEC4E, IL1B, CYLD, BCL3, ITPR1, TNF, CBLB, CALM2, MAPK14 | More | | Valsartan | hsa04640 | Hematopoietic cell lineage | 2.36E-05 | 17 | P13612, P14778, P27930, P11215, P15144, P11836, P25063, P07766, P09693, P01732, P01730, P06127, P09564, P13765, P01375, P09603, P01584 | ITGA4, IL1R1, IL1R2, ITGAM, ANPEP, MS4A1, CD24, CD3E, CD3G, CD8A, CD4, CD5, CD7, HLA-DOB, TNF, CSF1, IL1B | More | | Valsartan | hsa04650 | Natural killer cell mediated cytotoxicity | 6.07E-09 | 13 | P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q13241, P26718, O14931, O75015, P26717, P26715 | PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P01375 | TNF | Tumor necrosis factor | 0.761 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.761 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P78314 | SH3BP2 | SH3 domain-binding protein 2 | 0.748 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.786 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.823 | Q13547 | HDAC1 | Histone deacetylase 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | 0.786 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O60880 | SH2D1A | SH2 domain-containing protein 1A | -0.788 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.707 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.719 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.82 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | 0.807 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.715 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13241 | KLRD1 | Natural killer cells antigen CD94 | -0.701 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.773 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.91 | Q13547 | HDAC1 | Histone deacetylase 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | 0.772 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.842 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26718 | KLRK1 | NKG2-D type II integral membrane protein | -0.81 | Q13547 | HDAC1 | Histone deacetylase 1 | O14931 | NCR3 | Natural cytotoxicity triggering receptor 3 | 0.735 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.892 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.92 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.913 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.896 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.846 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26717 | KLRC2 | NKG2-C type II integral membrane protein | -0.721 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.846 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.714 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P26715 | KLRC1 | NKG2-A/NKG2-B type II integral membrane protein | -0.721 |
| Valsartan | hsa04657 | IL-17 signaling pathway | 3.02E-05 | 8 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375, P01584 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF, IL1B | More | | Valsartan | hsa04658 | Th1 and Th2 cell differentiation | 5.15E-07 | 15 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, Q14765, P23771, Q9UL17, P14784, P13765, P23458, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, JAK1, RUNX3 | More | | Valsartan | hsa04659 | Th17 cell differentiation | 3.79E-07 | 18 | Q04759, Q16539, P19174, P01730, P06239, P14784, P13765, P14778, Q9UL17, P23771, P84022, Q13485, P01584, P08238, P07766, P09693, P20963, P23458 | PRKCQ, MAPK14, PLCG1, CD4, LCK, IL2RB, HLA-DOB, IL1R1, TBX21, GATA3, SMAD3, SMAD4, IL1B, HSP90AB1, CD3E, CD3G, CD247, JAK1 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P01730 | CD4 | T-cell surface glycoprotein CD4 | 0.756 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.788 | Q13547 | HDAC1 | Histone deacetylase 1 | P14784 | IL2RB | Interleukin-2 receptor subunit beta | 0.816 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P13765 | HLA-DOB | HLA class II histocompatibility antigen, DO beta chain | -0.785 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.764 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.807 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q9UL17 | TBX21 | T-box transcription factor TBX21 | -0.872 | Q13547 | HDAC1 | Histone deacetylase 1 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.817 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | Q9UL17 | TBX21 | T-box transcription factor TBX21 | 0.731 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23771 | GATA3 | Trans-acting T-cell-specific transcription factor GATA-3 | -0.763 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | -0.838 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.777 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.758 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P23458 | JAK1 | Tyrosine-protein kinase JAK1 | 0.757 |
| Valsartan | hsa04660 | T cell receptor signaling pathway | 1.71E-07 | 17 | P01375, P25963, Q9UDY8, Q04759, P42338, P10747, O95267, Q08881, P19174, P07766, P20963, P09693, P01732, Q13191, P06239, Q16539, P49841 | TNF, NFKBIA, MALT1, PRKCQ, PIK3CB, CD28, RASGRP1, ITK, PLCG1, CD3E, CD247, CD3G, CD8A, CBLB, LCK, MAPK14, GSK3B | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | P08246 | ELA2 | Neutrophil elastase | P01375 | TNF | Tumor necrosis factor | 0.751 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P01375 | TNF | Tumor necrosis factor | 0.718 | P08246 | ELA2 | Neutrophil elastase | P25963 | NFKBIA | NF-kappa-B inhibitor alpha | 0.701 | P08246 | ELA2 | Neutrophil elastase | Q9UDY8 | MALT1 | Mucosa-associated lymphoid tissue lymphoma translocation protein 1 | -0.896 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q04759 | PRKCQ | Protein kinase C theta type | -0.767 | Q13547 | HDAC1 | Histone deacetylase 1 | Q04759 | PRKCQ | Protein kinase C theta type | 0.723 | P08246 | ELA2 | Neutrophil elastase | Q04759 | PRKCQ | Protein kinase C theta type | -0.748 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | P08246 | ELA2 | Neutrophil elastase | P10747 | CD28 | T-cell-specific surface glycoprotein CD28 | -0.854 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.852 | P08246 | ELA2 | Neutrophil elastase | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.724 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | -0.716 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.866 | P08246 | ELA2 | Neutrophil elastase | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.782 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.746 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q08881 | ITK | Tyrosine-protein kinase ITK/TSK | -0.736 | Q13547 | HDAC1 | Histone deacetylase 1 | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | 0.7 | Q13547 | HDAC1 | Histone deacetylase 1 | P07766 | CD3E | T-cell surface glycoprotein CD3 epsilon chain | 0.802 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.786 | Q13547 | HDAC1 | Histone deacetylase 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | 0.87 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.722 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P20963 | CD247 | T-cell surface glycoprotein CD3 zeta chain | -0.771 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.835 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P09693 | CD3G | T-cell surface glycoprotein CD3 gamma chain | -0.77 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.781 | Q13547 | HDAC1 | Histone deacetylase 1 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | 0.816 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P01732 | CD8A | T-cell surface glycoprotein CD8 alpha chain | -0.722 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.803 | Q13547 | HDAC1 | Histone deacetylase 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | 0.806 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.719 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q13191 | CBLB | E3 ubiquitin-protein ligase CBL-B | -0.734 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P06239 | LCK | Tyrosine-protein kinase Lck | -0.726 | Q13547 | HDAC1 | Histone deacetylase 1 | P06239 | LCK | Tyrosine-protein kinase Lck | 0.811 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P06239 | LCK | Tyrosine-protein kinase Lck | -0.779 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.883 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.889 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.795 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.812 | P25025 | CXCR2 | C-X-C chemokine receptor type 2 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.861 | P25024 | CXCR1 | C-X-C chemokine receptor type 1 | P49841 | GSK3B | Glycogen synthase kinase-3 beta | 0.823 |
| Valsartan | hsa04662 | B cell receptor signaling pathway | 1.74E-02 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Valsartan | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Valsartan | hsa04666 | Fc gamma R-mediated phagocytosis | 2.22E-02 | 4 | P49006, P06396, P14598, P17252 | MARCKSL1, GSN, NCF1, PRKCA | More | | Valsartan | hsa04668 | TNF signaling pathway | 3.24E-04 | 12 | P01375, O00463, Q13489, P25963, Q99941, P18848, P01584, P20749, Q13077, P14780, P20333, O95429 | TNF, TRAF5, BIRC3, NFKBIA, CREBL1, ATF4, IL1B, BCL3, TRAF1, MMP9, TNFRSF1B, BAG4 | More | | Valsartan | hsa04670 | Leukocyte transendothelial migration | 4.20E-02 | 7 | P14780, Q96A32, P17252, P14598, Q15080, Q08881, P42681 | MMP9, MYLPF, PRKCA, NCF1, NCF4, ITK, TXK | More | | Valsartan | hsa04720 | Long-term potentiation | 3.70E-04 | 5 | P17252, Q16566, P0DP23, O15399, Q14643 | PRKCA, CAMK4, CALM1, GRIN2D, ITPR1 | More | | Valsartan | hsa04724 | Glutamatergic synapse | 2.72E-03 | 5 | P48058, P43003, P63218, P50151, P15104 | GRIA4, SLC1A3, GNG5, GNG10, GLUL | More | | Valsartan | hsa04727 | GABAergic synapse | 3.89E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Valsartan | hsa04728 | Dopaminergic synapse | 2.82E-02 | 6 | P14416, P63218, P50151, P49841, Q16539, P49407 | DRD2, GNG5, GNG10, GSK3B, MAPK14, ARRB1 | More | | Valsartan | hsa04750 | Inflammatory mediator regulation of TRP channels | 4.09E-05 | 12 | P14778, P01584, P51828, P22694, Q13557, Q16539, P19174, P42338, Q14643, P24723, Q04759, P0DP24 | IL1R1, IL1B, ADCY7, PRKACB, CAMK2D, MAPK14, PLCG1, PIK3CB, ITPR1, PRKCH, PRKCQ, CALM2 | More | | Valsartan | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | | Valsartan | hsa04911 | Insulin secretion | 1.48E-02 | 3 | P51828, Q99941, Q13557 | ADCY7, CREBL1, CAMK2D | More | | Valsartan | hsa04912 | GnRH signaling pathway | 5.11E-03 | 8 | P17252, P51828, Q16539, Q9Y6R4, Q14643, P0DP24, P0DP23, P22694 | PRKCA, ADCY7, MAPK14, MAP3K4, ITPR1, CALM2, CALM1, PRKACB | More | | Valsartan | hsa04915 | Estrogen signaling pathway | 4.72E-02 | 4 | Q99941, P51828, P07900, P11142 | CREBL1, ADCY7, HSP90AA1, HSPA8 | More | | Valsartan | hsa04916 | Melanogenesis | 3.55E-02 | 3 | P0DP23, Q9UJU2, P17252 | CALM1, LEF1, PRKCA | More | | Valsartan | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | | Valsartan | hsa04920 | Adipocytokine signaling pathway | 4.49E-02 | 4 | P25963, P33121, Q04759, P01375 | NFKBIA, ACSL1, PRKCQ, TNF | More | | Valsartan | hsa04921 | Oxytocin signaling pathway | 4.19E-02 | 4 | P0DP23, P17252, Q16566, P63261 | CALM1, PRKCA, CAMK4, ACTG1 | More | | Valsartan | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Valsartan | hsa04925 | Aldosterone synthesis and secretion | 5.60E-06 | 9 | Q14643, Q99941, P51828, P0DP23, P17252, Q16566, Q13557, P20020, P23634 | ITPR1, CREBL1, ADCY7, CALM1, PRKCA, CAMK4, CAMK2D, ATP2B1, ATP2B4 | More | | Valsartan | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | | Valsartan | hsa04932 | Non-alcoholic fatty liver disease | 2.05E-03 | 5 | O43521, P18848, O75460, P01584, P13073 | BCL2L11, ATF4, ERN1, IL1B, COX4I1 | More | | Valsartan | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 2.93E-03 | 7 | P84022, Q13485, P10415, P42338, P49767, P17252, P19174 | SMAD3, SMAD4, BCL2, PIK3CB, VEGFC, PRKCA, PLCG1 | More | | Valsartan | hsa04934 | Cushing syndrome | 3.48E-03 | 4 | Q99941, P51828, O15169, Q13557 | CREBL1, ADCY7, AXIN1, CAMK2D | More | | Valsartan | hsa04950 | Maturity onset diabetes of the young | 2.03E-02 | 1 | P35557 | GCK | More | | Valsartan | hsa04962 | Vasopressin-regulated water reabsorption | 1.80E-02 | 2 | P62491, P46459 | RAB11A, NSF | More | | Valsartan | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | | Valsartan | hsa04966 | Collecting duct acid secretion | 2.32E-03 | 3 | P02730, P00918, Q9Y666 | SLC4A1, CA2, SLC12A7 | More | | Valsartan | hsa04970 | Salivary secretion | 1.38E-04 | 7 | P22694, Q14643, P20020, P23634, P17252, P0DP23, P49913 | PRKACB, ITPR1, ATP2B1, ATP2B4, PRKCA, CALM1, CAMP | More | | Valsartan | hsa04971 | Gastric acid secretion | 1.87E-03 | 6 | P51828, P17252, P15311, P63261, P0DP23, Q13557 | ADCY7, PRKCA, VIL2, ACTG1, CALM1, CAMK2D | More | | Valsartan | hsa04972 | Pancreatic secretion | 1.00E-02 | 3 | Q14643, P20020, P17252 | ITPR1, ATP2B1, PRKCA | More | | Valsartan | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Valsartan | hsa04976 | Bile secretion | 2.79E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | | Valsartan | hsa04978 | Mineral absorption | 3.94E-02 | 2 | P23634, Q9BXS9 | ATP2B4, SLC26A6 | More | | Valsartan | hsa05010 | Alzheimer disease | 1.70E-03 | 11 | Q92542, P05496, P13073, P12074, O75460, P0DP24, P01584, P18848, O15169, P05141, P45880 | NCSTN, ATP5G1, COX4I1, COX6A1, ERN1, CALM2, IL1B, ATF4, AXIN1, SLC25A5, VDAC2 | More | | Valsartan | hsa05012 | Parkinson disease | 3.89E-02 | 5 | P13073, P05141, O75460, P18848, P0DP24 | COX4I1, SLC25A5, ERN1, ATF4, CALM2 | More | | Valsartan | hsa05014 | Amyotrophic lateral sclerosis | 4.31E-02 | 7 | O15399, P10415, Q13509, P68371, Q53GS7, P63261, Q9GZY0 | GRIN2D, BCL2, TUBB3, TUBB2C, GLE1, ACTG1, NXF2; NXF2B | More | | Valsartan | hsa05016 | Huntington disease | 4.87E-02 | 5 | P13073, P24928, P62487, P05141, O75460 | COX4I1, POLR2A, POLR2G, SLC25A5, ERN1 | More | | Valsartan | hsa05020 | Prion disease | 1.81E-02 | 7 | P01584, P46531, P11142, P05496, P12074, P45880, Q99941 | IL1B, NOTCH1, HSPA8, ATP5G1, COX6A1, VDAC2, CREBL1 | More | | Valsartan | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.98E-02 | 7 | P13073, O75460, P18848, P05141, P20333, P01584, P0DP24 | COX4I1, ERN1, ATF4, SLC25A5, TNFRSF1B, IL1B, CALM2 | More | | Valsartan | hsa05031 | Amphetamine addiction | 1.49E-02 | 4 | O15399, P0DP23, Q16566, P17252 | GRIN2D, CALM1, CAMK4, PRKCA | More | | Valsartan | hsa05034 | Alcoholism | 3.90E-04 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Valsartan | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.22E-06 | 7 | Q16539, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Valsartan | hsa05131 | Shigellosis | 3.34E-02 | 11 | P01375, P25963, O00463, Q04759, Q9UDY8, Q9H1Y0, Q14643, Q12778, Q13315, P10415, Q96A32 | TNF, NFKBIA, TRAF5, PRKCQ, MALT1, ATG5, ITPR1, FOXO1, ATM, BCL2, MYLPF | More | | Valsartan | hsa05132 | Salmonella infection | 3.70E-05 | 16 | P51617, P25963, P01375, Q9UJU2, P63261, Q13546, Q13489, P10415, O75369, Q96A32, O60603, Q9BQS8, P51808, Q13561, Q13509, P68371 | IRAK1, NFKBIA, TNF, LEF1, ACTG1, RIPK1, BIRC3, BCL2, FLNB, MYLPF, TLR2, FYCO1, DYNLT3, DCTN2, TUBB3, TUBB2C | More | | Valsartan | hsa05133 | Pertussis | 1.79E-04 | 4 | P0DP23, P23528, P09871, P0C0L4 | CALM1, CFL1, C1S, C4A | More | | Valsartan | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Valsartan | hsa05135 | Yersinia infection | 4.65E-02 | 5 | P13612, P06239, Q16539, P01375, P49841 | ITGA4, LCK, MAPK14, TNF, GSK3B | More | | Valsartan | hsa05140 | Leishmaniasis | 7.13E-07 | 13 | P13612, O75015, P14598, P23458, P13765, O60603, P25963, P01375, P01584, P49006, Q16539, P51617, Q15080 | ITGA4, FCGR3B, NCF1, JAK1, HLA-DOB, TLR2, NFKBIA, TNF, IL1B, MARCKSL1, MAPK14, IRAK1, NCF4 | More | | Valsartan | hsa05143 | African trypanosomiasis | 1.74E-03 | 2 | P69905, P68871 | HBA2, HBB | More | | Valsartan | hsa05144 | Malaria | 1.66E-06 | 8 | P60033, P69905, P68871, O60603, P01375, P35443, P01584, P26718 | CD81, HBA2, HBB, TLR2, TNF, THBS4, IL1B, KLRK1 | More | | Valsartan | hsa05145 | Toxoplasmosis | 3.07E-02 | 7 | P51617, P25963, P01375, P10415, Q13489, P13765, O60603 | IRAK1, NFKBIA, TNF, BCL2, BIRC3, HLA-DOB, TLR2 | More | | Valsartan | hsa05146 | Amoebiasis | 2.28E-09 | 14 | P01584, Q13751, P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | IL1B, LAMB3, CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01584 | IL1B | Interleukin-1 beta | 0.807 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | Q13751 | LAMB3 | Laminin subunit beta-3 | -0.763 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.716 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P09341 | CXCL1 | Growth-regulated alpha protein | 0.788 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P09341 | CXCL1 | Growth-regulated alpha protein | 0.7 | Q13547 | HDAC1 | Histone deacetylase 1 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.736 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P09341 | CXCL1 | Growth-regulated alpha protein | -0.839 | Q13547 | HDAC1 | Histone deacetylase 1 | P19875 | CXCL2 | C-X-C motif chemokine 2 | -0.862 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.822 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.766 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | 0.76 | Q13547 | HDAC1 | Histone deacetylase 1 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.854 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P14778 | IL1R1 | Interleukin-1 receptor type 1 | -0.807 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.953 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.926 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | 0.811 | Q13547 | HDAC1 | Histone deacetylase 1 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.837 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P27930 | IL1R2 | Interleukin-1 receptor type 2 | -0.726 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P01375 | TNF | Tumor necrosis factor | 0.761 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P01375 | TNF | Tumor necrosis factor | 0.78 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.762 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | O60603 | TLR2 | Toll-like receptor 2 | 0.842 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | O60603 | TLR2 | Toll-like receptor 2 | 0.73 | Q13547 | HDAC1 | Histone deacetylase 1 | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | -0.774 | Q13547 | HDAC1 | Histone deacetylase 1 | P11215 | ITGAM | Integrin alpha-M | -0.751 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P05089 | ARG1 | Arginase-1 | 0.819 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P05089 | ARG1 | Arginase-1 | 0.848 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | P05089 | ARG1 | Arginase-1 | 0.702 | Q13547 | HDAC1 | Histone deacetylase 1 | P05089 | ARG1 | Arginase-1 | -0.769 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P05089 | ARG1 | Arginase-1 | -0.793 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P22694 | PRKACB | cAMP-dependent protein kinase catalytic subunit beta | -0.708 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P22694 | PRKACB | cAMP-dependent protein kinase catalytic subunit beta | -0.772 | Q13547 | HDAC1 | Histone deacetylase 1 | P12814 | ACTN1 | Alpha-actinin-1 | -0.887 | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | P12814 | ACTN1 | Alpha-actinin-1 | -0.814 | Q16769 | QPCT | Glutaminyl-peptide cyclotransferase | P08311 | CTSG | Cathepsin G | 0.715 | P43490 | PBEF1 | Nicotinamide phosphoribosyltransferase | P08311 | CTSG | Cathepsin G | 0.744 |
| Valsartan | hsa05152 | Tuberculosis | 2.07E-02 | 9 | Q13488, P48382, O60603, P01375, P10415, P13765, P49913, Q9UDY8, P51617 | TCIRG1, RFX5, TLR2, TNF, BCL2, HLA-DOB, CAMP, MALT1, IRAK1 | More | | Valsartan | hsa05161 | Hepatitis B | 2.33E-02 | 8 | P17252, P14780, P25963, P01375, P10415, P51617, O60603, Q14765 | PRKCA, MMP9, NFKBIA, TNF, BCL2, IRAK1, TLR2, STAT4 | More | | Valsartan | hsa05163 | Human cytomegalovirus infection | 1.87E-03 | 10 | P01375, P63218, P50151, Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | TNF, GNG5, GNG10, ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | | Valsartan | hsa05168 | Herpes simplex virus 1 infection | 1.94E-02 | 9 | Q9UKJ0, P01568, Q9GZY0, Q01130, Q13489, Q13398, Q03923, Q9UDV6, P10415 | PILRB, IFNA21, NXF2; NXF2B, SFRS2, BIRC3, ZNF211, ZNF85, ZNF212, BCL2 | More | | Valsartan | hsa05169 | Epstein-Barr virus infection | 2.15E-03 | 10 | P13765, Q92769, P04637, Q13546, P10415, P24522, O60603, P29728, P51617, P09693 | HLA-DOB, HDAC2, TP53, RIPK1, BCL2, GADD45A, TLR2, OAS2, IRAK1, CD3G | More | | Valsartan | hsa05170 | Human immunodeficiency virus 1 infection | 2.45E-05 | 16 | P0DP23, P01375, P17252, Q13546, O00463, Q14643, P51617, P25963, O60603, Q13315, O95067, P09693, P10415, Q13619, Q93034, Q9Y6Q5 | CALM1, TNF, PRKCA, RIPK1, TRAF5, ITPR1, IRAK1, NFKBIA, TLR2, ATM, CCNB2, CD3G, BCL2, CUL4A, CUL5, AP1M2 | More | | Valsartan | hsa05200 | Pathways in cancer | 9.22E-05 | 32 | Q13751, P42338, P08238, P19174, P04637, Q9UJU2, P17252, Q09472, P43246, P84022, Q13485, Q13547, P14923, P30281, P10415, Q13489, Q13077, P49767, P43657, P25116, P63218, P50151, Q14344, O95267, Q7LDG7, P78417, P24522, O75293, P0DP23, P01568, P14784, P16871 | LAMB3, PIK3CB, HSP90AB1, PLCG1, TP53, LEF1, PRKCA, EP300, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, BCL2, BIRC3, TRAF1, VEGFC, P2RY5, F2R, GNG5, GNG10, GNA13, RASGRP1, RASGRP2, GSTO1, GADD45A, GADD45B, CALM1, IFNA21, IL2RB, IL7R | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P32248 | CCR7 | C-C chemokine receptor type 7 | P04637 | TP53 | Cellular tumor antigen p53 | 0.77 | P46091 | GPR1 | Chemerin-like receptor 2 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.736 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.813 | P46091 | GPR1 | Chemerin-like receptor 2 | P17252 | PRKCA | Protein kinase C alpha type | 0.741 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q09472 | EP300 | Histone acetyltransferase p300 | -0.791 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P46091 | GPR1 | Chemerin-like receptor 2 | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.838 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.809 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P46091 | GPR1 | Chemerin-like receptor 2 | P14923 | JUP | Junction plakoglobin | 0.883 | P32248 | CCR7 | C-C chemokine receptor type 7 | P14923 | JUP | Junction plakoglobin | 0.711 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P46091 | GPR1 | Chemerin-like receptor 2 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.808 | P32248 | CCR7 | C-C chemokine receptor type 7 | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.748 | P46091 | GPR1 | Chemerin-like receptor 2 | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.759 | P32248 | CCR7 | C-C chemokine receptor type 7 | Q13077 | TRAF1 | TNF receptor-associated factor 1 | 0.748 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P46091 | GPR1 | Chemerin-like receptor 2 | P49767 | VEGFC | Vascular endothelial growth factor C | 0.718 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P46091 | GPR1 | Chemerin-like receptor 2 | P25116 | F2R | Proteinase-activated receptor 1 | 0.76 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P32248 | CCR7 | C-C chemokine receptor type 7 | O95267 | RASGRP1 | RAS guanyl-releasing protein 1 | 0.792 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P46091 | GPR1 | Chemerin-like receptor 2 | P78417 | GSTO1 | Glutathione S-transferase omega-1 | 0.738 | P32248 | CCR7 | C-C chemokine receptor type 7 | P24522 | GADD45A | Growth arrest and DNA damage-inducible protein GADD45 alpha | -0.862 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P46091 | GPR1 | Chemerin-like receptor 2 | P0DP23 | CALM1 | Calmodulin-1 | -0.846 | P46091 | GPR1 | Chemerin-like receptor 2 | P01568 | IFNA21 | Interferon alpha-21 | 0.724 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 | P32248 | CCR7 | C-C chemokine receptor type 7 | P16871 | IL7R | Interleukin-7 receptor subunit alpha | 0.743 |
| Valsartan | hsa05202 | Transcriptional misregulation in cancer | 1.15E-06 | 22 | Q12778, Q15532, Q13315, P17844, P14780, P27930, P14923, Q16548, Q13489, Q13077, O15550, P04637, P35226, P05164, P12838, P08246, Q9C0K0, P41182, Q13547, Q92769, P12980, P24522 | FOXO1, SS18, ATM, DDX5, MMP9, IL1R2, JUP, BCL2A1, BIRC3, TRAF1, UTX, TP53, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, HDAC1, HDAC2, LYL1, GADD45A | More | | Valsartan | hsa05203 | Viral carcinogenesis | 2.93E-03 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | | Valsartan | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | | Valsartan | hsa05206 | MicroRNAs in cancer | 2.97E-03 | 6 | P15311, P21860, P61978, P46531, P63279, P22105 | VIL2, ERBB3, HNRPK, NOTCH1, UBE2I, TNXB | More | | Valsartan | hsa05210 | Colorectal cancer | 2.41E-02 | 4 | P10415, P04637, Q9UJU2, P24522 | BCL2, TP53, LEF1, GADD45A | More | | Valsartan | hsa05212 | Pancreatic cancer | 9.39E-03 | 5 | P42338, P37173, P84022, Q13485, O75293 | PIK3CB, TGFBR2, SMAD3, SMAD4, GADD45B | More | | Valsartan | hsa05213 | Endometrial cancer | 1.91E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Valsartan | hsa05214 | Glioma | 8.71E-04 | 5 | P0DP23, Q16566, P17252, P04637, P24522 | CALM1, CAMK4, PRKCA, TP53, GADD45A | More | | Valsartan | hsa05215 | Prostate cancer | 1.94E-02 | 4 | P10415, Q9UJU2, Q09472, P04637 | BCL2, LEF1, EP300, TP53 | More | | Valsartan | hsa05216 | Thyroid cancer | 2.42E-04 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | | Valsartan | hsa05217 | Basal cell carcinoma | 2.82E-04 | 5 | Q13635, P49841, Q9UJU2, P04637, P24522 | PTCH1, GSK3B, LEF1, TP53, GADD45A | More | | Valsartan | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Valsartan | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Valsartan | hsa05222 | Small cell lung cancer | 1.93E-03 | 7 | Q13489, P10415, P25963, Q13077, O00463, P04637, P24522 | BIRC3, BCL2, NFKBIA, TRAF1, TRAF5, TP53, GADD45A | More | | Valsartan | hsa05224 | Breast cancer | 5.34E-03 | 5 | Q9UJU2, P49841, Q92837, P04637, P24522 | LEF1, GSK3B, FRAT1, TP53, GADD45A | More | | Valsartan | hsa05226 | Gastric cancer | 8.86E-03 | 5 | Q9UJU2, P04637, P24522, P14923, P10415 | LEF1, TP53, GADD45A, JUP, BCL2 | More | | Valsartan | hsa05230 | Central carbon metabolism in cancer | 4.04E-02 | 2 | P07195, P04637 | LDHB, TP53 | More | | Valsartan | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 2.22E-04 | 12 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, P23458, O60603, Q04759, Q16539, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, JAK1, TLR2, PRKCQ, MAPK14, CD4 | More | | Valsartan | hsa05310 | Asthma | 3.88E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Valsartan | hsa05321 | Inflammatory bowel disease | 4.27E-04 | 7 | O60603, P01375, P13765, Q14765, Q9UL17, P23771, P01584 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3, IL1B | More | | Valsartan | hsa05322 | Systemic lupus erythematosus | 2.47E-05 | 12 | P08246, P08311, P09871, P01375, P10747, P13765, Q6FI13, Q93077, P62807, O60814, P68431, P05455 | ELA2, CTSG, C1S, TNF, CD28, HLA-DOB, H2AC18; H2AC19, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, SSB | More | | Valsartan | hsa05332 | Graft-versus-host disease | 9.30E-03 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Valsartan | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | | Valsartan | hsa05418 | Fluid shear stress and atherosclerosis | 3.35E-05 | 12 | Q16539, P78417, P10599, P14780, P01375, P63261, P04637, P10415, P14778, P27930, P0DP23, Q92974 | MAPK14, GSTO1, TXN, MMP9, TNF, ACTG1, TP53, BCL2, IL1R1, IL1R2, CALM1, ARHGEF2 | More | | |